BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company, headquartered in Indianapolis, Indiana. The one-month return of Eli Lilly and Company (NYSE:LLY) was -13.90%, and its shares gained 32 ...

Dave Ricks, the CEO of Indianapolis-based Eli Lilly and Co., is the recipient of the 2024 August M. Watanabe Life Sciences Champion of the Year Award. Ricks received the award Thursday during ...

Eli Lilly and Company Stock Up 0.3 % Shares of NYSE LLY opened at $909.15 on Wednesday. The firm’s 50-day moving average price is $921.67 and its 200-day moving average price is $860.45. The ...

INDIANAPOLIS (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker ...

Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading pharmaceutical company that sells Trulicity, Verzenio, and Taltz drugs. The company discovers, develops, and markets human ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

They have Europe covered from one side to the other," said Indianapolis International Airport Executive Director Mario Rodriguez. The local business and medical community, particularly Eli Lilly ...

Eli Lilly has seen massive returns this year and is one of the most expensive healthcare stocks in the world. Its new products have strong growth prospects, but their potential may still be ...

Eli Lilly said on Monday it sued three medical ... and misleading consumers about the clinical data used to back them. The Indianapolis-based drugmaker has already sued more than two dozen ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

Eli Lilly's business is growing fast, but it wasn't enough for analysts and investors. It also slashed its earnings guidance for the year. The stock has been trading at a high valuation ...